

STATE OF NEW YORK

8345--B

2023-2024 Regular Sessions

IN ASSEMBLY

December 13, 2023

Introduced by M. of A. RAJKUMAR, L. ROSENTHAL, SEAWRIGHT -- read once and referred to the Committee on Health -- recommitted to the Committee on Health in accordance with Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- again reported from said committee with amendments, ordered reprinted as amended and recommitted to said committee

AN ACT in relation to requiring the department of health to report on the feasibility of establishing a generic drug manufacturing program aimed at reducing the cost of prescription drugs and to address shortages in the market for generic prescription drugs

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1 Section 1. On or before January first, two thousand twenty-six, the
2 department of health shall submit a report to the legislature that
3 assesses the feasibility of establishing a generic drug manufacturing
4 program aimed at reducing the cost of prescription drugs and to address
5 shortages in the market for generic prescription drugs by directly manu-
6 facturing generic prescription drugs and selling generic prescription
7 drugs at a fair price. The report shall conduct an analysis of gover-
8 nance structure options for manufacturing functions, including charter-
9 ing a private organization, a public-private partnership, or a public
10 board of directors. Additionally, the report shall include, but not be
11 limited to an analysis of the:

12 (a) feasibility of entering into a partnership with a drug manufactur-
13 er to produce insulin and generic drugs for chronic and high-cost condi-
14 tions;

15 (b) feasibility of entering into a partnership with a drug manufactur-
16 er to produce and make generic prescription drugs widely available;

17 (c) generic prescription drugs that would have the greatest impact on
18 lowering drug costs to patients, including high-cost drugs, high utili-

EXPLANATION--Matter in italics (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD08090-04-4

1 zation drugs, or drugs experiencing shortages in the market which the
2 program may prioritize;

3 (d) amount of staff required to oversee and manage the partnerships
4 for manufacturing or distribution of generic prescription drugs;

5 (e) research and development costs and start up costs associated with
6 the generic drug manufacturing program; and

7 (f) volume of generic prescription drugs and insulin that can be
8 produced over the first five years of the program.

9 § 2. This act shall take effect on the first of January next succeed-
10 ing one year after it shall have become a law.